Genmab Shares Rise 4% After FDA Approves Partnered Cancer Drug
Genmab shares rose 4% after FDA approval of a Johnson & Johnson-partnered cancer drug, sharpening focus on its oncology strategy.
Novocure Shares Slide After FDA Rejects Optune Mya Brain Metastases Application
Novocure shares were reported lower after the FDA issued a Not Approvable Letter for Optune Mya, clouding the company’s expansion strategy.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Phio Pharmaceuticals Moves PH-762 Toward Phase 2b After Q3 Update
Phio Pharmaceuticals is preparing PH-762 for a potential Phase 2b study as FDA discussions become the next key test for …
Novartis’s Pelacarsen Trial Failure Challenges the Lp(a) Drug Thesis
Pelacarsen’s failed cardiovascular outcomes trial raises questions for Novartis, Lp(a)-targeting therapies and cardiolog…
Pfizer’s Monthly GLP-1 Strategy Could Challenge Lilly and Novo Nordisk
Pfizer’s reported 12% weight-loss result and monthly dosing strategy could reshape expectations for the obesity-drug mar…
Corvus Rally Puts Cash Runway and Soquelitinib Milestones in the Spotlight
CRVS rose 8.53% after its Q3 call, putting cash runway and upcoming soquelitinib milestones at the center of the biotech…
CAPR Traders Position for FDA Decision as Hiring Clues Fuel Retail Speculation
CAPR rose more than 4% overnight as retail traders debated whether hiring listings signal launch preparations ahead of a…
Moderna’s Dual US-Canada Vaccine Wins Put Respiratory Portfolio in Focus
Moderna’s US and Canadian vaccine authorizations sharpen the case for a broader respiratory franchise beyond COVID-19 pr…
Gilead Shares a New Livdelzi Catalyst as Phase 3 PBC Data Move Toward Regulatory Talks
Positive Phase 3 IDEAL data for Livdelzi could give Gilead a regulatory catalyst and strengthen its non-HIV pipeline div…
Palatin Technologies Regains Buy Rating as Analysts Highlight Melanocortin Pipeline
H.C. Wainwright resumed coverage of Palatin with a buy rating, highlighting Vyleesi, MC4R expertise and prior business-d…
Edgewise Therapeutics Shares Jump on Takeover Interest Report: What Traders Should Watch
EWTX gained after a report of takeover interest, putting deal-premium speculation and catalyst-driven volatility at the …